Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg;Estudio doble ciego de la eficacia y la seguridad de la combinación a dosis fija de 10 mg de enalapril/20 mg de nitrendipino en comparación con el incremento de dosis de amlodipino en pacientes con hipertensión esencial no controlada con 5 mg de amlodipino

Revista Clinica Espanola

Volumn 205, Issue 9, 2005, Pages 418-424

  Marin Iranzo R ^a   de la Siera Iserte, A ^b   Roca Cusachs, A ^c   Olivan Martinez J ^d   Redon Mas J ^e   Luque Otero, M ^f   de la Figuera von Wichman, M ^g   Pontes Garcia C ^h   Delgadillo Duarte, J ^h   Abellan J ⁱ   Aracil, J ^j   Aranda, P ^k   Arrieta, J ^l   Artigao, M ^m   Ballve J L ⁿ   Cano, A ^o   Divison J A ^p   Fernandez C ^q   Fernandez F ^r   Gil Extremera, B ^s   Gorostidi, M ^t   Guerediaga, J ^u   Jimenez M J ^v   Laporta, F ^w   Ledesma, A ^x   Liebana A ^y   Lopez de Coca E ^z   Maria Orte L M ^aa   Ocon J ^ab   Olmos, J R ^ac   Pascual, J M ^ad   Pladevall, M ^ae   Plana, J ^af   Prieto, M A ^ag   Pujol, M ^ah   Redon J ^e   Robles Perez N R ^ai   Sobrino, J ^aj   Suarez C ^r   Tornero, F ^ak   Combalia J ^h   Teran M ^h   more..

^a Hospital Nuestra Senora de Covadonga   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g Centro de Salud la Mina   (Spain)

^h Vita Invest SA   (Spain)

ⁱ Primary Care Center   (Spain)

^j CS El Cristo   (Spain)

^k HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^l Hospital Nuestra Senora de Aranzazu   (Spain)

^m CS de Villacerrada   (Spain)

ⁿ CAP Florida Sud   (Spain)

^o Laboratori Bon Pastor   (Spain)

^p CS de Fuentealbilla   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^r HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^s HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^t Hospital Comarcal de Jarrio   (Spain)

^u HOSPITAL SAN AGUSTÍN   (Spain)

^v HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^w Health Care Service of Castilla La Mancha   (Spain)

^x CAP El Remei   (Spain)

^y Hosp Univ Ciudad de Jaén   (Spain)

^z CS Chinchilla   (Spain)

^aa HOSPITAL RAMÓN Y CAJAL   (Spain)

^ab FUNDACIÓ PUIGVERT   (Spain)

^ac HOSPITAL UNIVERSITARIO LA FE   (Spain)

^ad HOSPITAL DE SAGUNTO   (Spain)

^ae HOSPITAL GENERAL DE VIC   (Spain)

^af Hospital Sant Camil   (Spain)

^ag CS Vallobín   (Spain)

^ah ABS Carmel   (Spain)

^ai HOSPITAL INFANTA CRISTINA   (Spain)

^aj Hospital Esperit Sant   (Spain)

^ak HOSPITAL VIRGEN DE LA LUZ   (Spain)

more..

Author keywords

Amlodipine; Antihypertensive treatment; Enalapril; Fixed dose combination; Hypertension; Nitrendipine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE BESYLATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE PLUS NITRENDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; MALE; SKIN MANIFESTATION; TREATMENT FAILURE;

EID: 27744569933     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079069     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Breen LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72.
2. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertension. 2003;21:1983-92.
3. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. Hipertensión. 2002;19 Supl 3:34-41.
4. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet. 1997;349:454-7.
5. Colhoun HN, Dong W, Pouler NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertension. 1998;16:747-52.
6. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment and control of hypertension in Canada. Am J Hypertension. 1997;10:1097-102.
7. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres MR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States: JAMA. 2003;289:2363-9.
8. Prisant L.M. Fixed dose combination in first line treatment of hypertension. J Hypertension. 2002;2 Suppl 1:S11-9.
9. Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Human Hypertension. 2002;16:75-8.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62.
11. Messerli FH. Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am J Hypertension. 1999;12:S86-90.
12. Weir MR. The rationale for combination versus single-entity therapy in the treatment of hypertension. Am J Hypertension. 1998;11 Suppl: S163-9.
13. Dahlöf B, Eggerttsen R, Hansson L. Calcium antagonists combined with β-blockers or ACE inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol. 1988;12 Suppl 6:S104-8.
14. Hansson L, Himmelmann A. Calcium antagonists in anthypertensive combination therapy. J Cardiovasc Pharmacol. 1991;18 Suppl 10: S76-80.
15. Menard J, Bellet M. Calcium antagonists - ACE inhibitors combination therapy: objectives and methodology of clinical development. Journal of Cardiovascular Pharmacology. 1993;21 Suppl 2:S49-54.
16. Holzgreve H. Combination of calcium antagonists and ACE inhibitors in hypertension. J Cardiovasc Pharmacol. 1997;30 Suppl 1:S24-9.
17. European Medicines Agency. Committee on Proprietary Medicinal Products. Note for Guidance on Fixed Combination Medicinal Products: CPMP/EWP/240/95.
18. European Medicines Agency. Committee on Proprietary Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Hypertension: CPMP/EWP/138/95.
19. Roca-Cusachs A, Torres F, Horas M, Ríos J, Calvo G, Delgadillo J, et al. Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design. J Cardiovasc Pharmacol 2001;38:840-9.
20. Roca-Cusachs A, Delgadillo J, and Spanish group for study of enalapril/nitrendipine. Efficacy of a fixed dose combination of enalapril/nitrendipine in patients not controlled with enalapril or nitrendipine monotherapy. Results of pooled analysis of two studies: ENEAS-1 and ENEAS-2 [abstract]. Am J Hypertens. 2002;15:48.
21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-64.
22. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46.
23. Waeber B, Borges ET, Christeler P, Guillaume-Gentil M, Hollenstein U, Mannhart M. Amlodipine compared to nitrendipine in hypertensive patients: the effects on toleration in relationship to the onset of action. Cardiology. 1992;80 Suppl 1:S46-S53.
24. Frishman WH, Brobyn R, Brown RD, Johnson BF, Reeves RL, Wombolt DG. A randomised placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S103-6.
25. Lorimer AR, Smedsrud T, Walker P, Tyler HM. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiol Pharmacol. 1988;12 Suppl 7:S89-93.
26. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-7.
27. Weir MR, Rosenberg C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropiridine calcium antagonists. Am J Hypertens. 2001;14:963-8.
28. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585-92.
29. Jouven X, Zureik M, Desnos M, Guerot C, Ducimetiere P. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001;50:373-8.